04.21.25 -- Rethinking CGT Biotech Growth & Investment With Audrey Greenberg

There are a number of technology solutions that, when applied to a cell and gene therapy workflow, can streamline development and improve workflow integration.

Explore the importance of adopting a Quality by Design (QbD) approach in the development process while integrating regulatory and CMC strategies for maximum efficiency and benefit.

See how this advanced SKPT-HEK293 4G9 was able to provide a robust, CGMP-ready solution for efficient viral vector production, supporting a range of AAV serotypes and CAR-T Lenti-viral vectors for scalable manufacturing.

Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

Infectious disease mAb therapies are entering clinical trials at a record pace. Review the trends driving the use of mAb treatments as well as key considerations to remain competitive in the race to market.

Explore a description of research grade and process development productions of rAAV6, both based on transient transfection of serum-free cells grown in suspension.

Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.

The development and production of CGTs presents unparalleled complexities. Learn how a partner with robust end-to-end services can help you overcome challenges at every step of the drug lifecycle.

Examine how a partnership leveraging expertise in production for high-quality CRISPR gRNAs as well as cGMP manufacturing is supporting the clinical translation of CRISPR genome editing technologies.